

SAVE THE DATE!
April 1, 2021



Vaccine-Based Prevention of Meningococcal B Disease: Tools for Interpreting and Implementing Recommendations

SAVE THE DATE | April 1, 2021 | 12:00-1:00pm PST

Overview

Meningococcal disease, specifically serotype B (MenB), is an ongoing problem in this country. The disease can develop from initial symptoms to death within 24 hours, and as many as 20% of survivors have permanent sequelae. Notably, incidence rates are often a misconception due to underdetection and under-reporting. Given how disabling this disease can be that could have been prevented with vaccination, it is essential health care workers delivering vaccinations enhance their standards of care in practice in order to deliver the highest rates of preventative care in this area. Our program will target health care providers working in the areas of pediatrics, adolescent health, college health, and immunization. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MenB vaccination.

Learning Objectives

At the conclusion of this activity, participants will be able to:

1. Differentiate between types of meningococcal vaccinations with respect to serotypes covered, administration schedule, impact on herd protection and tolerability.
2. Interpret Category A and B recommendations in order to better discuss meningococcal B vaccination for patients.
3. Utilizing case-based video vignettes, implement strategies to improve uptake of meningococcal B vaccine in clinical practice.

Speakers

Theresa M. Fiorito, MD
Assistant Professor
Department of Pediatrics
NYU Long Island School of Medicine

Gary Marshall, MD
Professor of Pediatrics
Chief, Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Louisville, KY

Accreditation

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

This educational activity is supported by an independent educational grant from GlaxoSmithKline.



Boston University School of Medicine
Barry M. Manuel Continuing Medical Education Office